Re-sensitization to pembrolizumab following PSMA-CD3 T-cell redirection therapy with JNJ-081 in a patient with mismatch repair-deficient metastatic castration-resistant prostate cancer: a case report

While checkpoint inhibitor therapy has revolutionized the treatment landscape of some solid tumors, it has shown limited efficacy in metastatic castration-resistant prostate cancers (mCRPC). A small (~3–5%) but clinically distinct subset of mCRPC tumors have a DNA mismatch repair deficiency (dMMR) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Reed-Perino, Darien E, Lai, Michael, Yu, Evan Y, Schweizer, Michael T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230978/
https://www.ncbi.nlm.nih.gov/pubmed/37220954
http://dx.doi.org/10.1136/jitc-2023-006794

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10230978/
https://www.ncbi.nlm.nih.gov/pubmed/37220954
http://dx.doi.org/10.1136/jitc-2023-006794

Ejemplares similares